黄芪丹参注射液与开博通联合应用治疗糖尿病肾病临床观察

Clinical observation of salvia miltiorrhiza and erigeron breviscapus injections and captopril on diabetic nephropathy(DN)

目的 :研究黄芪及丹参注射液与开博通联合应用治疗糖尿病肾病的疗效。方法 :选择糖尿病肾病 32例。其中早期糖尿病肾病 1 9例 ,临床期糖尿病肾病 1 3例 ,每期分为联合用药组及单用开博通对照组。开博通 37.5～ 75mg/d,联合用药组在用开博通的基础上 ,每日静滴黄芪注射液40 ml及丹参注射液 30 ml,并检测 2 4 h尿白蛋白排泄率、肌酐清除率、血 β2 - MG、尿 β2 - MG、血胆固醇、甘油三酯及 HDL。结果 :联合用药可以降低早期糖尿病肾病尿白蛋白排泄率及肌酐清除率效果好于单用开博通组 (P<0 .0 1 ) ,且发现联合用药可以降低临床期糖尿病肾病尿蛋白 ,升高肌酐清除率及 HDL ,降低血胆固醇、甘油三酯、血β2 - MG及尿β2 - MG(P<0 .0 1 )。结论 :本研究证实了中药黄芪、丹参注射液与开博通联合应用治疗糖尿病肾病 ,更有助于改善肾小球滤过率 ,减少尿蛋白 。

Objective: To study the curative effects of salvia miltiorrhiza and Erigeron breviscapus injections and Capoten(Captopril) on diabetic nephropathy(DN) Methods: To select 32 cases of DN, 19 cases of Mogensen Ⅲ stage and 13 cases of Mogensen Ⅳ stage,then to divide them into two groups: one group is cured with combined medicines, the other is cured with Capoten 375to 75 mg Capoten was taken daily in Capoten group, at the same time, 30 ml salvia miltiorrhiza injection and 40 ml Erigeron breviscapus injection were dripped intravenously on base of taking Capoten daily in combined medicines group Results:The UAE and Ccr levels of early DN in combined medicines group are significantly lower than in Capoten group (P<001); on clinic stage of DN,combined medicines can decrease urinary protein, increase urinary Ccr,HDL and lower the blood and urinary β 2MG level; on both early stage and clinic stage of DN,combined medicines can also decrease serum CHO and TG in addition to increasing HDL(P<005)Conclusion: The curative effect of combined medicines on DN is better than Capoten